Dasolampanel

Dasolampanel

Systematic (IUPAC) name
(3S,4aS,6S,8aR)-6-(3-Chloro-2-(1H-tetrazol-5-yl)phenoxy)decahydroisoquinoline-3-carboxylic acid
Identifiers
CAS Number	503294-13-1
ATC code	None
PubChem	CID: 51049972
ChemSpider	25948207
UNII	1P85D6BE9K Y
Chemical data
Formula	C17H20ClN5O3
Molecular mass	377.825 g/mol
SMILES c1cc(c(c(c1)Cl)c2[nH]nnn2)O[C@H]3CC[C@H]4CN[C@@H](C[C@H]4C3)C(=O)O
InChI InChI=1S/C17H20ClN5O3/c18-12-2-1-3-14(15(12)16-20-22-23-21-16)26-11-5-4-9-8-19-13(17(24)25)7-10(9)6-11/h1-3,9-11,13,19H,4-8H2,(H,24,25)(H,20,21,22,23)/t9-,10+,11-,13-/m0/s1 Key:LAKQPSQCICNZII-NOHGZBONSA-N

Dasolampanel (INN, USAN, code name NGX-426) is an orally bioavailable analog of tezampanel and thereby competitive antagonist of the AMPA and kainate receptors which was under development by Raptor Pharmaceuticals/Torrey Pines Therapeutics for the treatment of chronic pain conditions including neuropathic pain and migraine. It was developed as a follow-on compound to tezampanel, as tezampanel is not bioavailable orally and must be administered by intravenous injection, but ultimately neither drug was ever marketed.

See also

• Irampanel
• Selurampanel